Drug recalls (page 8)

748 recalls.

• MOTRIN 2'S DISP.- 50CT recall (GOLD STAR DISTRIBUTION INC)
  DrugClass IIReported January 21, 2026 · CGMP Deviations: Insanitary conditions including rodent exposure/activity in their distribution center.
• EXCEDRIN MIGRAINE 2'S- 25 CT recall (GOLD STAR DISTRIBUTION INC)
  DrugClass IIReported January 21, 2026 · CGMP Deviations: Insanitary conditions including rodent exposure/activity in their distribution center.
• EXCEDRIN 2'S DISP.- 30 CT recall (GOLD STAR DISTRIBUTION INC)
  DrugClass IIReported January 21, 2026 · CGMP Deviations: Insanitary conditions including rodent exposure/activity in their distribution center.
• LIQUID DAYQUIL 12/8oz recall (GOLD STAR DISTRIBUTION INC)
  DrugClass IIReported January 21, 2026 · CGMP Deviations: Insanitary conditions including rodent exposure/activity in their distribution center.
• DAYQUIL COLD & FLU recall (GOLD STAR DISTRIBUTION INC)
  DrugClass IIReported January 21, 2026 · CGMP Deviations: Insanitary conditions including rodent exposure/activity in their distribution center.
• Claritin recall (GOLD STAR DISTRIBUTION INC)
  DrugClass IIReported January 21, 2026 · CGMP Deviations: Insanitary conditions including rodent exposure/activity in their distribution center.
• Bayer 2Pk- 25 CT recall (GOLD STAR DISTRIBUTION INC)
  DrugClass IIReported January 21, 2026 · CGMP Deviations: Insanitary conditions including rodent exposure/activity in their distribution center.
• Benadryl recall (GOLD STAR DISTRIBUTION INC)
  DrugClass IIReported January 21, 2026 · CGMP Deviations: Insanitary conditions including rodent exposure/activity in their distribution center.
• Alka Seltzer recall (GOLD STAR DISTRIBUTION INC)
  DrugClass IIReported January 21, 2026 · CGMP Deviations: Insanitary conditions including rodent exposure/activity in their distribution center.
• Aleve 1's recall (GOLD STAR DISTRIBUTION INC)
  DrugClass IIReported January 21, 2026 · CGMP Deviations: Insanitary conditions including rodent exposure/activity in their distribution center.
• Advil a) Ibuprofen recall (GOLD STAR DISTRIBUTION INC)
  DrugClass IIReported January 21, 2026 · CGMP Deviations: Insanitary conditions including rodent exposure/activity in their distribution center.
• AQ 120 GFEW recall (Encon Safety Products Co)
  DrugClass IIReported January 21, 2026 · cGMP deviations.
• Levothyroxine Sodium Tablets recall (Alvogen, Inc)
  DrugClass IIReported January 21, 2026 · Product Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets.
• Clindamycin Phosphate USP recall (SUN PHARMACEUTICAL INDUSTRIES INC)
  DrugClass IIIReported January 21, 2026 · Failed Impurities/Degradation: Out of Specification results for Total Impurities and for Assay.
• Fluocinolone Acetonide Solution Topical Solution USP recall (SUN PHARMACEUTICAL INDUSTRIES INC)
  DrugClass IIIReported January 21, 2026 · Failed Impurities/Degradation Specifications: Out of specification result was obtained for the known impurity D.
• Rosuvastatin Tablets recall (AvKARE)
  DrugClass IIReported January 14, 2026 · Out of specification for dissolution.
• ClearLife Allergy Nasal Spray recall (Medinatura New Mexico, inc.)
  DrugClass IReported January 14, 2026 · Microbial Contamination of Non-Sterile Products: The products have been found to contain yeast/mold and microbial contamination identified as Achromobacter.
• ReBoost Nasal Spray recall (Medinatura New Mexico, inc.)
  DrugClass IReported January 14, 2026 · Microbial Contamination of Non-Sterile Products: The products have been found to contain yeast/mold and microbial contamination identified as Achromobacter.
• Oxycodone and Acetaminophen CII Tablets USP recall (SpecGx, LLC)
  DrugClass IIReported January 14, 2026 · Failed Tablet/Capsule Specification: There is a potential for the imprint to be missing on tablets.
• Oxycodone and Acetaminophen CII Tablets USP recall (SpecGx, LLC)
  DrugClass IIReported January 14, 2026 · Failed Tablet/Capsule Specification: There is a potential for the imprint to be missing on tablets.
• ORL Kids Natural Toothpaste recall (Signature Formulations, LLC)
  DrugClass IIReported January 14, 2026 · cGMP Deviations
• ORL Kids Mouthwash recall (Signature Formulations, LLC)
  DrugClass IIReported January 14, 2026 · cGMP Deviations
• Tri-Moxi+¿ recall (Imprimis NJOF, LLC)
  DrugClass IIReported January 14, 2026 · Presence of particulate matter - Glass like particles.
• Dexamethasone Moxifloxacin Ketorolac recall (Imprimis NJOF, LLC)
  DrugClass IIReported January 14, 2026 · Presence of particulate matter - Glass like particles.
• Dexamethasone Moxifloxacin recall (Imprimis NJOF, LLC)
  DrugClass IIReported January 14, 2026 · Presence of particulate matter - Glass like particles.
• Fesoterodine Fumarate recall (Alembic Pharmaceuticals Limited)
  DrugClass IIIReported January 14, 2026 · Failed Impurities/Degradation Specifications: Due to levels of 'Diester Impurity' exceeding the specification limit.
• traZODONE Hydrochloride Tablets recall (Zydus Pharmaceuticals (USA) Inc)
  DrugClass IIIReported January 7, 2026 · Failed Tablet/Capsule Specifications: Product complaint received that some tablets had a dent on the plain side of the tablet surface.
• Ondansetron Orally Disintegrating Tablets recall (Glenmark Pharmaceuticals Inc., USA)
  DrugClass IIReported January 7, 2026 · Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets...
• Wegovy recall (Novo Nordisk Inc.)
  DrugClass IIReported January 7, 2026 · Presence of Particulate Matter: Hair was found in a prefilled syringe
• Wegovy recall (Novo Nordisk Inc.)
  DrugClass IIReported January 7, 2026 · Presence of Particulate Matter: Hair was found in a prefilled syringe
• BD ChloraPrep" Triple Swabsticks recall (CareFusion 213, LLC)
  DrugClass IIReported January 7, 2026 · Lack of Assurance of Sterlity
• Noxafil Powdermix recall (Merck Sharp & Dohme LLC)
  DrugClass IIReported December 31, 2025 · Presence of particulate matter: potential presence of metal particulates in the product.
• Merck Emend recall (Merck Sharp & Dohme LLC)
  DrugClass IIReported December 31, 2025 · Presence of particulate matter: potential presence of metal particulates in the product.
• Ciclopirox Shampoo recall (SUN PHARMA /TARO)
  DrugClass IIReported December 24, 2025 · Failed Impurity/Degradation specifications: OOS results obtained at the 18-month timepoint
• Ondansetron ODT Tablets recall (Preferred Pharmaceuticals, Inc.)
  DrugClass IIReported December 24, 2025 · Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets...
• Cisatracurium Besylate Injection USP recall (SOMERSET THERAPEUTICS LLC)
  DrugClass IIIReported December 24, 2025 · Subpotent product:out of specification assay results observed during long term stability testing.
• Cisatracurium Besylate Injection USP recall (SOMERSET THERAPEUTICS LLC)
  DrugClass IIIReported December 24, 2025 · Subpotent product:out of specification assay results observed during long term stability testing.
• Cisatracurium Besylate Injection USP recall (SOMERSET THERAPEUTICS LLC)
  DrugClass IIIReported December 24, 2025 · Subpotent product:out of specification assay results observed during long term stability testing.
• Baclofen Tablets USP recall (Golden State Medical Supply Inc.)
  DrugClass IIReported December 24, 2025 · Presence of Foreign Tablets/Capsules
• Cinacalcet Hydrochloride Tablets recall (Cipla USA, Inc.)
  DrugClass IIReported December 17, 2025 · CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
• Cinacalcet Hydrochloride Tablets recall (Cipla USA, Inc.)
  DrugClass IIReported December 17, 2025 · CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
• Cinacalcet Hydrochloride Tablets recall (Cipla USA, Inc.)
  DrugClass IIReported December 17, 2025 · CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
• Morphine Sulfate Oral Solution 100 mg / 5 mL recall (Winder Laboratories, LLC)
  DrugClass IIIReported December 17, 2025 · Correct Labeled Product Mispack-Size stated on carton label did not match the size of the bottle in the carton.
• Nebivolol Tablets recall (Glenmark Pharmaceuticals Inc., USA)
  DrugClass IIIReported December 17, 2025 · Cross Contamination with Other Products
• Tropicamide 1%/Cyclopentolate 1%/Phenylephrine 2.5%/Ketorolac 0.5% Topical Ophthalmic... recall (Fagron Compounding Services)
  DrugClass IIReported December 17, 2025 · Incorrect Product Formulation
• Duloxetine Delayed-Release Capsules recall (Breckenridge Pharmaceutical, Inc.)
  DrugClass IIReported December 10, 2025 · CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
• Duloxetine Delayed-Release Capsules recall (Breckenridge Pharmaceutical, Inc.)
  DrugClass IIReported December 10, 2025 · CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
• Bisoprolol Fumarate and Hydrochlorothiazide Tablets recall (Glenmark Pharmaceuticals Inc., USA)
  DrugClass IIIReported December 10, 2025 · Cross Contamination with Other Products: Testing of reserve samples showed presence of traces of ezetimibe

← Newer